Lokoid Lipokrem cream 0.1%, 30 g

• Superficial, uninfected, sensitive to local GCS skin diseases: eczema;

• dermatitis (including atopic, contact, seborrheic);

• psoriasis;

• reactions to insect bites;

• itching of various etiologies.

The drug is applied to the affected skin with a thin layer 1-3 times a day. If positive dynamics appear, the frequency of application of the drug can be reduced to 2-3 times a week. To improve penetration, the drug is applied with massaging movements. In cases of a resistant course of diseases, for example, with the localization of dense psoriatic plaques on the elbow areas, knees, the drug can be used under occlusive dressings. The dose of the drug used during the week should not exceed 30-60 g.

Cream for external use 0.1% white, homogeneous.

1 g

hydrocortisone 17-butyrate 1 mg

Excipients: liquid paraffin - 180 mg, white soft paraffin - 420 mg, cetostearyl alcohol - 60 mg, cetomacrogol 25 - 30 mg, propyl parahydroxybenzoate - 0.5 mg, benzyl alcohol - 5 mg, anhydrous citric acid - 1.8 mg, sodium citrate anhydrous - 1.2 mg, purified water - 300.5 mg.

• Bacterial skin infections (strepto- and staphyloderma, gram-negative folliculitis);

• viral skin infections (herpes simplex, chickenpox, shingles);

• fungal infections of the skin;

• tuberculous and syphilitic skin lesions;

• parasitic skin infections;

• neoplastic skin changes (benign and malignant tumors);

• acne, rosacea, perioral dermatitis;

• post-vaccination period;

• violation of the integrity of the skin (wounds, ulcers);

• hypersensitivity to the drug;

• pregnancy, lactation.

pharmachologic effect

GCS for external use, synthetic non-halogenated compound. Esterification of the hydrocortisone molecule with a butyric acid residue (butyrate) made it possible to radically increase the activity of this substance in comparison with native hydrocortisone. It has a fast-onset anti-inflammatory, anti-edema, antipruritic effect.

Application in recommended doses does not cause suppression of the hypothalamic-pituitary-adrenal system. Although the use of high doses for a long time, especially when using occlusive dressings, can lead to an increase in the content of cortisol in the blood plasma, this is usually not accompanied by a decrease in the reactivity of the pituitary-adrenal system, and the cessation of use leads to a rapid normalization of cortisol production.

Pharmacokinetics

After application, the active substance accumulates in the epidermis, mainly in the granular layer, systemic absorption is negligible. A small amount of hydrocortisone 17-butyrate is absorbed unchanged into the systemic circulation. Most of the hydrocortisone 17-butyrate is metabolized to hydrocortisone and other metabolites directly in the epidermis and subsequently in the liver. Metabolites and a small part of unchanged hydrocortisone 17-butyrate are excreted by the kidneys and through the intestines.

Side effect

Local reactions: skin irritation; in rare cases, other local reactions characteristic of GCS therapy.

Systemic reactions: with prolonged use, application to large surfaces and / or the use of occlusive dressings, side effects characteristic of systemic corticosteroids may occur. The risk of local and systemic side effects is lower than with fluorinated steroids.

Application during pregnancy and lactation

Contraindicated during pregnancy and lactation (breastfeeding).

Application in children

Can be used in children from 6 months of age.

special instructions

Should not be applied to the periorbital area due to the risk of glaucoma. With a systematic contact with the conjunctiva, there is a risk of increased intraocular pressure.

With severe lichenification, dryness, hyperkeratosis, it is better to use it in the form of an ointment or lip cream.

Not recommended for use in the presence of atrophic skin changes.

The risk of local and systemic side effects increases when applied to large areas of the lesion, prolonged use, the use of occlusive dressings and in childhood.

If there is no effect within 2 weeks of continuous treatment, the diagnosis should be clarified.

As with the use of any GCS, it is desirable to limit the duration of use and prescribe a course dose, the minimum sufficient to stop the skin process.

Use in pediatrics

Can be used in children from 6 months of age. In cases of using the drug in children, on the face area or under occlusive dressings, the duration of the course of treatment should be reduced. When used in children, the surface area of ??the skin on which the drug is applied should not exceed 20% of the total.

In childhood, suppression of adrenal cortex function may develop more rapidly. In addition, there may be a decrease in the excretion of growth hormone. When used for a long time, it is necessary to monitor body weight, growth, plasma cortisol levels. In a study in children who received 30-60 g per week for 4 weeks in comparison with 1% hydrocortisone ointment, no child was found to have dysfunction of the adrenal cortex, while the differences between hydrocortisone 17-butyrate in this indicator from conventional hydrocortisone was not observed.